期刊
NEUROIMAGING CLINICS OF NORTH AMERICA
卷 20, 期 3, 页码 425-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.nic.2010.04.007
关键词
Targeted therapy; Glioblastoma; Tyrosine kinase inhibitors; Clinical trials
资金
- Chris Elliott Fund for Glioblastoma Brain Cancer Research
The prognosis for glioblastoma is poor despite optimal therapy with surgery, radiation, and chemotherapy. New therapies that improve survival and quality of life are needed. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression. Novel agents have been developed against these targets, including receptor tyrosine kinases, intracellular signaling molecules, epigenetic abnormalities, and tumor vasculature and microenvironment. This article reviews novel therapies for glioblastoma, with an emphasis on targeted agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据